Zefei

Zefei

gemcitabine

Manufacturer:

Jiangsu Hansoh

Distributor:

Goodfellow
Concise Prescribing Info
Contents
Gemcitabine HCl
Indications/Uses
Dosage/Direction for Use
Adult Pancreatic cancer (as single agent) 1000 mg/m2 by 30 min IV infusion once wkly for up to 7 wk, followed by 1 wk rest period. Subsequent cycle should consist of once wkly infusion for 3 consecutive wk every 4 wk. Non-small cell lung cancer (as combination) 4-wk schedule: 1000 mg/m2 by 30 min IV infusion on days 1, 8 & 15 of each 28-day cycle + cisplatin 100 mg/m2 IV on day 1 after gemcitabine infusion. 3-wk schedule: 1250 mg/m2 by 30 min IV infusion on days 1 & 8 of each 21-day cycle + cisplatin 100 mg/m2 IV on day 1 after gemcitabine infusion.
Special Precautions
Monitor complete blood count including differential & platelet, leukocyte & granulocyte count. Consider suspension or modification of therapy upon detection of marrow suppression. Prolonged infusion time beyond 60 min. Renal & hepatic impairment, pregnancy.
Adverse Reactions
Anemia, leukocytopenia, thrombocytopenia, elevation of liver transaminase enzymes or alkaline phosphatase, nausea & vomiting, diarrhea or mild constipation, moderate proteinuria & hematuria, dyspnea, allergic skin reactions, anaphylactoid reaction, somnolence, flu-like symptoms, edema, alopecia, oral soreness & erythema.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01BC05 - gemcitabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Zefei powd for inj 1 g
Packing/Price
1's
Form
Zefei powd for inj 200 mg
Packing/Price
(vial) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in